Table 1 Demographics and patient characteristics—historical comparator and clinical trial data

From: Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia

  Historical data set Clinical trial data
  Patients with CR data Patients with OS data Blinatumomab trial (MT103-211)
  N=694 N=1112 N=189a
Sex, n (%)
 Male 421 (60.7) 644 (57.9) 119 (63%)
 Female 273 (39.3) 468 (42.1) 70 (37%)
Mean (s.d.) age, years 38.8 (14.8) 37.4 (14.2) 41.1 (17.3)
Age group (years)
 18–34 317 (45.6) 527 (47.4) 90 (48)
 35–54 256 (36.9) 428 (38.5) 46 (24)
55 80 (11.5) 115 (10.3) 53 (28)
65 41 (5.9) 42 (3.8) 25 (13)
Disease status, n (%)
 Primary refractory    16 (8.5)
In 1st salvage 61 (8.8) 56 (5.0) 4 (2.1)
In 2nd or greater salvage 50 (7.2) 61 (5.5) 12 (6.3)
 Relapsed, with prior alloHSCT    64 (33.9)
In 1st salvage 44 (6.3) 130 (11.7) 9 (4.8)
In 2nd or greater salvage 45 (6.5) 57 (5.1) 55 (29.1)
 Relapsed, without prior alloHSCT    109 (57.7)
In 1st salvage 245 (35.3) 543 (48.8) 25 (13.2)
In 2nd or greater salvage 249 (35.9) 265 (23.8) 84 (44.4)
Year of initial diagnosis, n (%)
 1990 to 1999 246 (35.4) 364 (32.7) 0 (0)
 2000 or later 448 (64.6) 748 (67.3) 189 (100)
Region, n (%)
 Europe 393 (56.6) 811 (72.9) 95 (50)
 USA 301 (43.4) 301 (27.1) 94 (50)
  1. aNumbers by salvage treatment in disease status categories not totalling due to missing data for salvage history (need to verify).